Printer Friendly

Natural product inhibitors of ovarian neoplasia. (Review).


The present work constitutes a review of the literature on natural products with potential antitumor activity against ovarian neoplasias. The review refers to five plant extracts and sixty-nine compounds isolated from higher plants and microorganisms, which are classified in appropriate chemical groups and model tested, and cites their activity. Some aspects of recent research with natural products directed to ward producing drugs which are inhibitors of ovarian neoplasia are discussed.

Key words: Ovarian, Neoplasia, Chemotherapy, Anticancer agent, Antitumor activity, Natural products, Medicinal plants


The life expectancy of patients with malignant neoplasias has increased in recent years, because of early diagnosis and improvements in chemotherapy. Other primary tumors have frequently been diagnosed in the same individual (Fishman, 1998). A trend toward definitive associations of multiple primary tumors has been observed. In women, neoplasias of breast and ovary are most frequently related (Curtin et al., 1994).

The structure and function of the ovaries varies with the age of the individual, being strongest prominent during child-bearing years and atrophying after menopause. The ovaries are two small almond-shaped bodies, dull white in color, measuring approximately 2 cm in length, 1.5 cm in breadth and 1 cm in thickness. They are situated on either side of the pelvis, attached to the posterior layer of the broad ligaments and lying inside the peritoneal cavity below the bifurcation of the common iliac artery, anterior to the sacroiliac joints. The attachment of the ovary to the posterior layer of the broad ligament is known as the mesovarium. The ovary is suspended from the uterine cornu by the ovarian ligament, which runs inside the broad ligament to the mesovarium. The lateral pole of the ovary is supported by the infundibulo-pelvic ligament, which runs to the sidewall of the pelvis (Lambert and Soutter, 1990).

In the course of our continuing search for bioactive natural products from plants and microorganisms used as anticancer agents, we recently published two reviews on crude plant extracts and chemically defined molecules with potential antitumor activity against mammary (Moura et al., 2001) and uterine cervical neoplasia (Moura et al., 2002). In the present work we have reviewed the literature related with natural products which specifically inhibit ovarian neoplasias.

Materials and methods

The keywords used for this review were medicinal plants, natural products, ovarian, tumor and chemotherapy. The search perfound using Chemical Abstracts, Biological Abstracts and the data bank of The University of illinois at Chicago, NAPRALERT (Acronym for NAtural PRoducts ALERT), updated to April 2001. The references obtained were later consulted.

Results and Discussion

Plants have been used as sources of medicinal agents for milennia. As the age of modem, scientific medicine and single pure drugs has evolved, plant-derived active principles and their semi-synthetic and synthetic analogs have served as a major spurce for new pharmaceuticals for treatment of malignant tumors, including ovarian neoplasia.

The peak incidence of ovarian cancer occurs in women between 50 and 60 years of age. The treatment includes the following modalities: surgery, radiotherapy, and chemotherapy. Because many patients have stage III and IV disease upon presentation, chemotherapy has assumed an increasingly important role in management.

Consultation of various types of literature sources resulted in the elaboration of a list of natural products evaluated specifically for ovarian neoplasias. It should be noted that most of the references cited are not firsthand observations, but secondary sources. For details on the models or mechanism-based bioassays utilized for selecting plant extracts and pure compounds against ovarian tumors, the original references should be consulted.

Plant extract inhibitors of ovarian neoplasia

Although plants have a long history of use in the treatment of cancer, many, if not all, of the claims for the efficacy of such treatments should be viewed with some skepticism because ovarian neoplasia, as a specific disease entity, is poorly defined in folkloric and traditional medicine. In fact, in our search of the literature we found only five plant extracts with indications for neoplasias of ovaries, namely:

* Hymenocardia acida, Mangifera indica and Sida rhombifolia: The evaluation of the anticancer activity of extracts from these three medicinal plants collected in Zaire was carried out using the U.S. National Cancer Institute panel of human tumor cell lines provided for the preliminary screening of natural products. Methanol extracts from the root bark of H. acida, the stem bark of M. indica and the leaves of S. rhombifolia exhibited in-vitro cytotoxic activity against 6 human cell lines tested. Of these, the methanol extracts of H. acida and M. indica are suitable candidates for bioactivity-directed fractionation to isolate the chemical constituents responsible for the observed antitumor effects (Table 1) (Muanza et al., 1995). These tumor systems are acceptable models for the corresponding human disease.

* Cinnamomum cassia: The aqueous extract of C. cassia is used traditionally in China, South Korea and Marroco for amenorrhea (Hu, 1982; Lee et al., 1977; Bellakhdar et al., 1991), and also in China to prevent postpartum blood clotting, but the effects described refer to a multi-component preparation (Sun, 1964). In India, C. cassia is used as an abortifacient (Saha et al., 1961). Scientific studies in China report that the aqueous extract showed antitumor activity in treating 10 cases of liver and ovarian cancer and leukemia (Hu, 1982).

* Viscum album: The use of V album (mistletoe, European parasite) as a medicine for circulatory and nervous disorders dates from antiquity. The herb contains choline and acetylcholine-tyramine substances which are known for their regulatory effect on blood pressure and circulation, and for toning the heart muscle (ZeeCheng, 1997).

Since the 1920s, extracts from V album have been popular in Europe as an unconventional approach for cancer treatment. Starke 60 is an aqueous extract isolated from fresh mistletoe, although reports of its preparation have not been published. One ampoule of 1 ml contains 60 mg of the mistletoe extract, mainly as cancerostatic protein. The compound was marketed by Novipharm GmbH as Isorel[R] in Austria in 1983 and as Vysorel(r) in Germany in 1986 (Zee-Cheng, 1997). Results of studies with ovarian cancers, advanced breast and other tumors treated with V album are summarized in Table 2. In general, results show improvements in DNA repair in lymphocytes, cell-mediated immunity and modest survival rates.

Chemically-defined molecule inhibitors of ovarian neoplasia

We encountered 69 chemically defined molecules obtained from natural sources reported in the literature as useful for treatment of ovarian neoplasia. Of these, 52 compounds are in pre-clinical studies and 17 are currently used clinically in the chemotherapeutic treatment of the disease.

Some of the compounds evaluated, listed in Table 4, could serve as new leads for antineoplasic agents in the future. Three heterocyclic compounds, mycalamide-A and -B and onnamide, were isolated from Mycale sp. and Theonella sp. sponges collected in New Zealand and Okinawan waters. Only mycalamide-A and -B were active against M5076 ovarian sarcoma. Mechanism of action studies indicate that the compounds inhibited protein synthesis (Burres and Clement, 1989). The antitumor activity of FR901228, a non-alkaloid N-heterocycle compound isolated from Chromobacterium violaceum, prolonged the life of mice, inhibiting the growth of murine solid tumor M5076 reticulum cell sarcoma. FR901228 was also more effective against mitomycin C-, cyclophosphamide-, vincristine- and 5-fluorouracil-resistant P388 leukemias than against non-resistant P388 in mice. These results suggest that FR901228 will be a new type of drug for the treatment of cancer (Ueda et al., 1994). The bulbs of Pancratium littorale collected in Hawaii were f ound to contain a new phenanthridone alkaloid designated pancratistatin that proved to be effective (53-84% life extension at 0.38-3.0 mg/kg dose levels) against in vivo murine M5076 ovarian sarcoma (Pettit et al., 1986). The results of the literature survey are presented in Table 3. The compounds are arranged in alphabetical order, with each entry giving the following information in sequence: chemical name, class, organism tested, model, result and references.

Ten plant-derived compounds have been approved for use as clinical anticancer drugs in different types of ovarian neoplasias: etoposide, irinotecan, mitoxantrone, taxol, taxotere, teniposide, topotecan, vinblastine, vincristine and vinorelbine. Another seven agents [actinomycin-D, adriamycin, bleomycin, daunorubicin, epirubicin, mitomycin C and peplomycin] are microorganism-derived compounds (Table 4). It has been shown that a combination of synthetic agents and drugs of natural origin appears to be more effective than single-agent therapy, which was the previously-accepted standard (Baker, 1981). For example, platinum drugs are standard in the treatment of patients with ovarian cancer but carboplatin-paclitaxel has recently become the standard chemotherapy regimen for patients with advanced ovarian cancer or recurrent ovarian cancer (De Furia, 1997; Pujade et al., 2000). Primary choriocarcinoma of the ovary (PCO) is rare; this can be gestational (GCO) or nongestational (NGCO) in origin. It is difficult to di fferentiate between CGO and NGCO, but NGCO has a worse prognosis than GCO. Two cases of metastatic GCO were treated successfully with combination chemotherapy (Cyclophosphamide-methotrexate as synthetic agents and actinomycin D-bleomycin-etoposide-vincristine as natural drugs) and the patients were alive and disease free at the time of the report (Gangadharan et al., 1999). Topotecan is an active drug in platinum-sensitive epithelial ovarian carcinoma, with significant but manageable hematologic toxicity (McGuire et al., 2000). Angiosarcomas rarely involve the female genital tract. There have only been sporadic case reports of angiosarcomas of the cervix, uterus, vagina, parametrium, broad ligament and pelvis, and only 1 well-documented case of primary ovarian angiosarcoma in the literature to date. A case of primary pure ovarian angiosarcoma that had partial response after chemotherapy with adriamycin and ifosfamide was reported (Twu et al., 1999). Small cell carcinoma of the ovary (SCCO) is a highly aggress ive malignancy which affects young females. The disease is fatal in nearly all patients with disease categorized as higher than stage IA. A 30-year-old woman was diagnosed, while pregnant, as having bilateral small cell carcinoma, pulmonary type, a rare finding. She received three courses of JP chemotherapy (carboplatina, 525 mg; cisplatina, 120 mg) and three courses of PVP chemotherapy (peplomycin, 30 mg; vin-blastin 12 mg; cisplatin, 120 mg). Computer tomography scans were taken during and after the period in which she received chemotherapy. These showed growing multiple metastatic tumors and massive ascites. Third-line chemotherapy with paclitaxel (225 mg) was then initiated. Although the lymphadenopathy and massive ascites were alleviated, bone marrow suppression intervened. The patient died 18 months after diagnosing (Kawasaki et al., 2000).

The results of the literature survey are presented in Table 4. The compounds are arranged in alphabetical order, each entry giving the following information: chemical name, trademark (listing of trademarks is for information purposes only and it should not be assumed that the trademarks are in current use), class, source and references. The chemical structure of compounds is shown in Fig. 1.

Of the 69 compounds which have been isolated and identified (Table 3 and 4) and are available for ovarian neoplasias, 25 are alkaloids, 8 non-alkaloid N-heterocycles, 7 miscellaneous lactones, 4 proteids, 4 diterpenes, 4 anthraquinones, 3 peptides, 2 quinoids, 2 triterpenes, 2 sesquiterpenes, 2 flavonoids, 2 lignans, 1 carbohydrate, 1 carotenoid, I anthracene and 1 benzenoid. This study has revealed that the most promising leads are alkaloids (Table 5).


Of all the gynecologic cancers, ovarian malignancies represent the greatest clinical challenge because early diagnosis is difficult. Ovarian cancer is one of the classic hidden malignancies in the abdomen. When a patient finally presents symptoms, the volume of the tumor is usually very high and most of the time metastasis had already occurred. In order to improve the survival rate for ovarian cancer, research effort needs to be directed towards early diagnosis and more effective drug therapy.

We can conclude that in spite of the large incidence of ovarian neoplasia, attacks women all over the world, there is little in the literature about the use of products of natural origin that inhibit this pathology. Even so, there is a large variety of plants and microorganisms on our planet yet to be explored and, there is thus potential for reaching a stage in the future when an ovarian tumor will no longer be a threat.
Table 1

Cytoxicity profiles of methanol extracts from Himenocardia acida,
Mangifera indica and Sida rhombifolia against ovarian neoplasia.

Ovarian Growth percentage (*)
models H. acida M. indica S. rhombifolia

IGROV-1 73.6 56.4 -35.1
OVCAR-3 11.5 31.0 -43.5
OVCAR-4 41.9 45.0 -1.4
OVCAR-5 46.8 54.6 -46.1
OVCAR-8 >100.0 53.3 -44.1
SK-OV-3 -23.8 51.7 -12.1

* Figures are "% Growth" relative to concomitant and zerotime controls.

If >100, then Stimulative

if 0 to 100, then Cytostatic/ Cytotoxic

if Negative, then Cytolytic.

Table 2

Reported treatment of cancer patients with Viscum album extract.

Cancer Treatment and results Reference

Advanced * The depression of cell-mediated Coeugniet, 1987
ovarian immunity was determined in
cancer patients with ovarian carcinoma
 using lymphokine production
 by conc A stimulation,
 T-lymphocyte transformation
 test, and a skin reactivity
 test with V. album extract.
 * 20 women: Stage I and II 5-year Hassauer et
 survival, 100%, III, 23%, IV, 0%. al., 1979
 Postoperative treatment with
 V. album, III, 4.2 times longer,
 IV, 1.6 times longer. V. album
 extract is a useful treatment
 for ovarian carcinoma

Breast * Natural killer and antibody- Hajto and
cancer dependent cell-mediated Lanzrein, 1986
 cytotoxicity, as well as the
 number of stage granular
 lymphocytes, as improved.
 * Assays of cell-mediated Coeugniet, 1987
 immunity in patients showed
 good results with treatment.
 * Improvement of DNA repair in Kovacs et
 lymphocytes of breast cancer al., 1991
 patients with treatment: 12/14
 patients showed an improvement
 (2.7 times) due to stimulation
 of repair enzyme by lymphokine
 or cytokine.
 * Postoperation therapy (547 Leroi, 1977
 patients) after surgery of
 breast neoplasm.
 Stage I and II, 5 and 10-year
 survival rates are significantly
 improved with postoperative use
 of V. album. No toxic side-effects.

Various * Various tumor growths and Schultze et
tumors therapies are studied and compared. al., 1991

Table 3

Preclinical studies of chemically defined molecules as inhibitors of
ovarian neoplasia model.

Chemical name Class tested Model

Abrin Proteid Human and Ca-Ovarian
Acivicin Alkaloid Mouse Ca-Ovarian M5076
Aclacinomycin A Quinoid Human Ca-Ovarian
Actinomycin, [beta]-Pip Non-alkaloid Mouse Ca-Ovarian M5076
Aphidicolin Diterpene Mouse Ca-Ovarian M5/DDP
Baccharin Sesquiterpene Mouse Ca-Ovarian M5076

Bryostatin 1 Miscellaneous Human and Ca-Ovarian M5076
 lactone mouse
Bullatacin Miscellaneous Mouse Ca-Ovarian A2780
Bullatacinone Miscellaneous Mouse Ca-Ovarian A2780
Colchicine Alkaloid Mouse Ca-Ovarian M5076
Dehydrodidemnin B Peptide Human Ca-Ovarian M5076
Didemnin B Peptide Human Ca-Ovarian M5076
Dolastatin 10 Proteid Mouse Ca-Ovarian OVCAR-3
Echinomycin Non-alkaloid Human Ca-Ovarian
Ecteinascidin 722 Non-alkaloid Mouse Ca-Ovarian M5076
Ecteinascidin 729 Non-alkaloid Mouse Ca-Ovarian M5076
Ecteinascidin 743 Alkaloid Mouse Ca-Ovarian HOC22

Elactocin Miscellaneous Mouse Ca-Ovarian M5076
Flavone acetic acid Flavonoid Mouse Ca-Ovarian IGROV-1
FR901228 Peptide Mouse Ca-Ovarian M5076
Ginsenoside RH-2 Triterpene Mouse Ca-Ovarian HRA

Gossypol Sesquiterpene Human Ca-Ovarian OVCAR-3
Homoharringtonine Alkaloid Human and Ca-Ovarian
Hydroquinone Benzenoid Mouse Ca-Ovarian M5076
Indeno alkaloid Alkaloid Mouse Ca-Ovarian M5076

Kazusamycin A Miscellaneous Mouse Ca-Ovarian M5076
Leurocristine Alkaloid Mouse Ca-Ovarian OVCAR-3
Radisky et al., 1993
Lycobetaine Alkaloid Human Ca-Ovarian
Lycopene Carotenoid Mouse Ca-Ovarian OVCAR-3

Makaluvamine A Alkaloid Mouse Ca-Ovarian OVCAR-3
Makaluvamine B Alkaloid Mouse Ca-Ovarian OVCAR-3
Makaluvamine C Alkaloid Mouse Ca-Ovarian OVCAR-3
Maytansine Non-alkaloid Human Ca-Ovarian
Methylnogarol Quinoid Mouse Ca-Ovarian M5076

Mycalamide A Alkaloid Mouse Ca-Ovarian MS 076

Mycalamide B Alkaloid Mouse Ca-Ovarian M5076

Nitidine Alkaloid Mouse Ca-Ovarian M5076

Onnamide Alkaloid Mouse Ca-Ovarian M5076

Pancratistatin Alkaloid Mouse Ca-Ovarian M5076
Polysacch. DS-4152 Carbohydrate Mouse Ca-Ovarian M5076
Pseudolaric acid B Diterpene Mouse Ca-Ovarian A2780

Quercetin Flavonoid Human Ca-Ovarian
Quinocarmycin Alkaloid Mouse Ca-Ovarian M5076
Rhizoxin Miscellaneous Human Ca-Ovarian
Ricin Proteid Mouse Ca-Ovarian

Rolliniastatin 2 Miscellaneous Mouse Ca-Ovarian A2780
Thiocolchicine Alkaloid Mouse Ca-Ovarian M5076
Trimethyl- Alkaloid Human Ca-Ovarian
 colchicinic acid
Vincaleukoblastine Alkaloid Human Ca-Ovarian
Viscum peptide Proteid Mouse Ca-Ovarian M5076
Vismione A Anthracene Mouse Ca-Ovarian M5076
Wortmannin Triterpene Mouse Ca-Ovarian M5076

Chemical name Result Reference

Abrin Active Tung et al, 1975;
 Fodstad et al., 1977
Acivicin Active Bogden et al., 1979
Aclacinomycin A Active Lev and Posada, 1983
Actinomycin, [beta]-Pip Inactive Parker et al., 1983

Aphidicolin Active Damia et al., 1992
Baccharin Active Douros and Suffness,
Bryostatin 1 Active Jayson et al., 1995;
 Hornung et al., 1992
Bullatacin Active Kinghorn and
 Balandrin, 1993
Bullatacinone Active Ahammadasahib
 et al., 1993
Colchicine Active Kerekes et al., 1985
Dehydrodidemnin B Active Rinehart, 2000
Didemnin B Inactive Malfetano et al., 1993
Dolastatin 10 Active Pettit et al., 1993
Echinomycin Active Muss et al., 1990

Ecteinascidin 722 Active Rinehart and Sakai,
Ecteinascidin 729 Active Rinehart and Sakai,
Ecteinascidin 743 Active Rinehart, 2000;
 Jimenoetal., 1996
Elactocin Active Pettit et al., 1994

Flavone acetic acid Active Pratesi et al., 1991
FR901228 Active Ueda, 1994
Ginsenoside RH-2 Active Tode et al., 1993;
 Nakata et al., 1998
Gossypol Active Bens et al., 1990
Homoharringtonine Inactive Kavanagh et al., 1984

Hydroquinone Inactive Arisawa et al., 1984
Indeno alkaloid Active Cushman and Mohan,
Kazusamycin A Active Pettit, 1994

Leurocristine Inactive Mattem et al., 1984;
Radisky et al., 1993
Lycobetaine Active Hsu, 1980; Hsu, 1981
Lycopene Active Levi and Sharoni,
Makaluvamine A Active Radisky et al., 1993
Makaluvamine B Inactiva Radisky et al., 1993
Makaluvamine C Active Radisky et al., 1993
Maytansine Active Chabner et al., 1978

Methylnogarol Active Douros and Suffness,
Mycalamide A Active Burres and Clement,
Mycalamide B Active Burres and Clement,
Nitidine Inactive Cushman and Mohan,
Onnamide Inactive Burres and Clement,
Pancratistatin Active Pettit et al., 1986
Polysacch. DS-4152 Active Tanaka et al., 1989
Pseudolaric acid B Active Kinghom and
 Balandrin, 1993
Quercetin Active Ferry et al., 1996
Quinocarmycin Active Fujimoto et al., 1987
Rhizoxin Inactive Kerr et al., 1995

Ricin Active Pihi et al., 1980; Pihl
 and Fodstad, 1983
Rolliniastatin 2 Active Ahammadasahib
 et al., 1993
Thiocolchicine Active Kerekes et al., 1985
Trimethyl- Active Ru et al., 1990
 colchicinic acid
Vincaleukoblastine Active Young et al., 1985
Viscum peptide Active Cassinelli et al., 1986
Vismione A Active Cassinelli et al., 1986
Wortmannin Active Schultze et al., 1995

Table 4

Clinical use of chemically defined molecules a inhibitors of ovarian

Chemical name Trademarker Class Source

Actinomycin-D Dactinomycin Non-alkaloid Streptomyces spp.

Adriamycin Doxorubicin Anthraquinone Streptomyces peucetius

Bleomycin Blenoxane Non-alkaloid Streptomyces verticillus

Daunorubicin Daunoblastina Anthraquinone Streptomyces peucetius

Epirubicin Farmorubicin Anthraquinone Analog of adriamycin D

Etoposide VP-16 Lignan Prepared from
 podophyllotoxin (1)

Irinotecan Camptosar, Alkaloid Prepared from
 CPT-11 camptothecin (2)

Mitomycin C Mutamycin Alkaloid Streptomyces caespitosus

Mitoxantrone Novantrone Anthraquinone Prepared from
 anthraquinone nucleus
Peplomycin Peplo Injection Non-alkaloid Derivative of bleomycin
Taxol Paclitaxel Diterpene Taxus brevifolia

Taxotere Docetaxel Diterpene Derivative of taxol

Teniposide VM-26 Lignan Prepared from
 podophyllotoxin (1)
Topotecan Hycamtin Alkaloid Prepared from
 camptothecin (2)
Vinblastine Velban Alkaloid Vinca rosea

Vincristine Oncovin Alkaloid Vinca rosea

Vinorelbine Navelvine Alkaloid Derivative of vinblastine

Chemical name Clinical use

Actinomycin-D * Coriocarcinoma of the ovary
 * Non-seminomatous tumor of the
 * Ovarian germ-cell malignancy
Adriamycin * Advanced ovarian cancer
 * Angiosarcoma of ovary

 * Clear-cell carcinoma of the ovary
Bleomycin * Coriocarcinoma of the ovary
 * Ovarian germ-cell malignancy
 * Non-seminomatous tumor of the
 * Granulose cell tumors of the
 * Ovarian dysgerminoma
 * Yolk sac tumor of the ovary
Daunorubicin * Advanced ovarian cancer
 * Granulocytic sarcoma of the ovary
Epirubicin * Advanced ovarian cancer

Etoposide * Advanced ovarian cancer
 * Coriocarcinoma of the ovary
 * Non-seminomatous tumor of the
 * Ovarian dysgerminoma
Irinotecan * Advanced ovarian cancer
 * Cystadenocarcinoma of the ovary
 * Clear-cell carcinoma of the ovary
Mitomycin C * Cystadenocarcinoma of the ovary
 * Clear cell carcinoma of the ovary
Mitoxantrone * Advanced ovarian cancer

Peplomycin * Small cell carcinoma of the ovary
 * Malignant ovarian tumors
Taxol * Small cell carcinoma of the ovary
 * Clear cell carcinoma of the ovary
 * Advanced ovarian cancer
 * Mullerian tumor of the ovary
Taxotere * Advanced ovarian cancer

Teniposide * Malignant ovarian tumors

Topotecan * Advanced ovarian cancer

Vinblastine * Small cell carcinoma of the ovary
 * Yolk sac tumor of the ovary
 * Malignant ovarian tumors
Vincristine * Coriocarcinoma of the ovary
 * Granulose-theca tumors of the
 * Malignant ovarian tumors
 * Non-seminomatous tumor of the
Vinorelbine * Advanced ovarian cancer

Chemical name Reference

Actinomycin-D Gangadharan et al., 1999
 Baranzelli et al., 2000

 Sumi et al., 2000
Adriamycin Yokoynma et al., 2000
 Di-Leo, 1999
 Platt et al., 1999
 Kita et al., 2000
Bleomycin Gangadharan et al., 1999
 Sumi et al., 2000
 Baranzelli et al., 2000

 Peeorelli et al., 1999

 Brewer et al., 1999
 Kawai et al., 1999
Daunorubicin Yokoyama et al., 2000
 Sreejith et al., 2000
Epirubicin Papadimitriou et al., 2000
 Pfisterer, 2000
Etoposide Li et al., 2000
 Gangadharan et al., 1999
 Baranzelli et al., 2000

 Brewer et al., 1999
Irinotecan Koshiyama et al., 2000
 Takizawa et al., 1997
 Shimizu et al., 1998
Mitomycin C Takizawa et al., 1997
 Umezawa et al., 1996
Mitoxantrone Topuz et al., 1998
 Le-Donne et al., 1997
Peplomycin Kawasaki et al., 2000
 Koyama et al., 1998
Taxol Kawasaki et al., 2000
 Patsner, 1998
 Schink et al., 2001
 Eltabbakh and yadav, 1999
Taxotere Markman et al., 2000
 Vasey et al., 1999
Teniposide Cheng et al., 1999

Topotecan Bookman et al., 1998
 Cacciari et al., 2000
Vinblastine Kawasaki et alk., 2000
 Kawai et al., 1999
 Herrmann, 1997
Vincristine Gangadharan et al., 1999
 Peeorelli et al., 1999

 Cesano et al., 1999
 Baranzelli et al., 2000

Vinorelbine Gershenson et a., 1998
 Burger et al., 1999
 Cicchetti et al., 2000

(1) Podophyllotoxin is a lignan isolated from Podophyllum peltatum

(2) Camptothecin is an alkaloid isolated from Camptotheca acuminata

Table 5

Rank of natural products that present activity in ovarian neoplasias.

Class Rank %

Alkaloids 37
Non-alkaloid N-heterocycles 13
Miscelaneous lactone 11
Diterpenes 6
Proteids 6
Anthraquinones 4
Peptides 4
Flavonoids 3
Lignans 3
Quinoids 3
Sesquiterpenes 3
Triterpenes 3
Anthracenes 1
Benzenoids 1
Carbohydrates 1
Carotenoids 1


The authors wish to express their sincere thanks to the College of Pharmacy, The University of Illinois at Chicago, Chicago, Illinois 60612-7231, U.S.A., for helping with the computer-aided NAPRALERT search.


Ahammadasahib KI, Hollingworth RM, McGovren JP, Hui YH, McLaughlin JL (1993) Mode of action of bullatacin: A potent antitumor and pesticidal annonaceous acetogenin. Life Sci 53: 1113-1120.

Arisawa M, Funayama S, Pezzuto JM, Kinghorn AD, Cordell GA, Farnsworth NR (1984) Potential anticancer agents. XXXII. Hydroquinone from Ipornopsis aggregata (Polemoniaceae). J Nat Prod 47: 3 93-394

Baker LH (1981) Gynecological cancers. In: Cancer and Chemotherapy (Ed Crooke ST, Prestayko AW), vol II, Academic Press, New York, 243-255

Baranzelli C, Bouffet E, Quintana E, Portas M, Thyss A, Patte C (2000) Non-seminomatous ovarian germ cell tumors in children. Eur J Cancer 36: 376-383

Bellakhdar J, Claisser R, Fleurentin J, Younos C (1991) Repertory of standard drugs in the Moroccan Pharmacopoea. J Ethnopharmacol 35: 123-143

Bens CC, Keniry MA, Ford JM, Townsend AJ, Cox FW, Palayoor S, Matlin SA, Hait WN, Cowan KH (1990) Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers. Mol Pharmacol 37: 840-847

Bogden AE, Neil GL, Houchens DP, Ovejera AA, Sheridan MA, Johnson RK (1979) Therapy for mouse tumors and human tumor xenografts with the antitumor antibiotic AT-125. Cancer Treat Rep 63: 473-476

Bookman MA, Malmstrom H, Bolis G, Gordon A, Lissoni A, Krebs JB, Fields SZ (1998) Topotecan for the treatment of advanced epithelial ovary cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16: 3345-3352

Brewer M, Gershenson D, Herzog CE, Follen M, Silva EG, Taylor WJ (1999) Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 17: 2670-2675

Burger RA, Disaia PJ, Roberts JA, Moore DH, Monk BJ (1999) Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol 72: 148-153

Burres NS, Clement JJ (1989) Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide. Cancer Res 49: 2935-2940

Cacciari N, Zaagni C, Martoni A (2000) The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer, is it possible only with peripheral blood stem cell support? Eur J Gynecol Oncol 21: 84-85

Cassinelli G, Geroni C, Botta B, Delle Monache G, Delle Monache F (1986) Cytotoxic and antitumor activity of vismiones isolated from Vismieae. J Nat Prod 49: 929-931

Cesano A, Lane SR, Poulin R, Ross G, Fields SZ (1999) Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. Int J Oncol 15: 1233-1238

Chabner BA, Levine AS, Johnson BL, Young RC (1978) Initial clinical trials of maytansine, an antitumor plant alkaloid. Cancer Treat Rep 62: 429-433

Cheng A, Peng Z, Hong Z (1999) A pharmacokinetic study of teniposide in intraperitoneal chemotherapy of ovarian cancer. J West China Univ Med Sci 30: 95-98

Cicchetti S, Jemec B, Gault DT (2000) Two case reports of vinorelbine extravasations: Management and review of the literature. Tumori 86: 289-292

Coeugniet EG (1987) Assay of the cell-mediated immunity in patients with malignant and non-malignant diseases. Onkologie 10: 22-26

Curtin J, Barakat RR, Hoskins WJ (1994) Ovarian disease in women with breast cancer. Obstet Gynecol 84: 449-452

Cushman M, Mohan P (1985) Synthesis and antitumor activity of structural analogues of the anticancer benzophenanthridine alkaloid fagaronine chloride. J Med Chem 28: 1031-1036

Damia G, Tagliabue G, Zucchetti M, Davoli E, Sessa C, Cavalli F, D'Incalci M (1992) Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin. Cancer Chemother Pharmacol 30: 459-464

De Furia MD (1997) Paclitaxel (Taxol[R]): A new natural product with major anticancer activity. Phytomedicine 4: 273-282

Di-Leo A (1999) New interesting medications in the treatment of ovarian cancer and in general in gynecological tumors. Tumori 85(Suppl 1): S27-S29

Douros JD, Suffness M (1981) New antitumor substances of natural origin. Cancer Treat Rep 8: 63-87

Eltabbakh GH, Yadav R (1999) Good response of malignant mixed mullerian tumor of the ovary to paclitaxel and cisplatin chemotherapy. Eur J Gynecol Oncol 20: 355-356

Ferry DR, Smith A, Malkhandi J, Fyfe DW, De Takats PG, Anderson D, Baker J, Kerr DJ (1996) Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2: 659-668

Fishman A (1998) A second primary malignancy in a cohort of patients with epithelial ovarian cancer: characteristics of diagnosis. Eur J Gynecol Oncol 19: 280-283

Fodstad O, Olsnes S, Pihl A (1977) Inhibitory effect of abrin and ricin on the growth of transplantable murine tumors and of abrin on human cancers in nude mice. Cancer Res 37: 4559-4561

Fujimoto K, Oka T, Morimoto M (1987) Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152). Cancer Res 47: 1516-1522

Gangadharan VP, Mathew BS, Kumar KS, Chitrathara K (1999) Primary choriocarcinoma of the ovary - Report of two cases. Indian Journal of Cancer 36: 213-215

Gershenson D, Burke TW, Morris M, Bast RC, Guaspari AI, Hohneker J, Wharton JT (1998) A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Gynecol Oncol 70: 404-409

Hajto T, Lanzrein N (1986) Natural killer and antibody dependent cell-mediated cytotoxicity activities and large granular lymphocyte frequencies in Viscum album-treated breast cancer patients. Oncology 43: 93-97

Hassauer W, Gutsch J, Bukhardt R (1979) What prospects of success does Iscador therapy offer in advanced ovarian cancer? Onkologie 2: 28-36

Herrmann R (1997) Chemotherapy of malignant diseases: Where is the much-anticipated progress? Schweiz Med Wochensch 127: 2138-2139

Hornung RI, Pearson JW, Beckwith M, Longo DI (1992) Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 52: 101-107

Hsu B (1980) Recent progress in antineoplastic drug research in China (Review). Cancer Research in the People's Republic of China and the United States of America -- Epidemiology, causation and approaches to therapy (ed Marks), Rune & Stratton, New York

Hsu B (1981) Pharmacology of some natural products of China. Tips 2: 271-272

Hu AB (1982) Ten cases of tumor treated by mainly using Cinnamomum cassia. Zhejiang-Zhongyi Zazhi 17: 60-61

Hu E, Ko R, Koda R, Rosen P, Jeffers S, Scholtz M, Muggia F (1990) Phase I toxicity and pharmacology study of trimethylcolchicinic acid in patients with advanced malignancies. Cancer Chemother Pharmacol 26: 359-364

Jayson GC, Crowther D, Prendiville I, McGown AT, Scheid C, Stem P, Young R, Brenchley P. Chang J, Owens S, Pettit GR (1995) A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24-hour intravenous infusion. Br J Cancer 72: 461-468

Jimeno J, Faircloth G, Cameron L, Meely K, Veja E, Gomez A, Sousa-Faro JMF, Rinehart KL (1996) Pogress in the acquisition of new marine-derived anticancer compounds: Development of ecteinascidin-743 (ET-743). Drugs of the Future 21: 1155-1165

Kavanagh JJ, Gershenson DM, Copeland LJ, Wharton JT, Rutledge FN, Krakoff IH (1984) Intermittent IV homoharringtonine for the treatment of refractory epithelial carcinoma of the ovary: a phase II trial. Cancer Treat Rep 68: 1503-1504

Kawai OY, Shibata D, Niwa Y, Suzuki Y, Kajiyama H, Kitagawa T, Wakahara Y, Kakihara M, Arii Y (1999) Primary chemotherapy in strongly susected yolk sac tumor of the ovary. Int J Clin Oncol 4: 48-51

Kawasaki F, Takai N, Narahara H, Yokoyama S, Miyakawa I (2000) A rare case of bilateral small cell carcinoma of the ovary diagnosed during pregnancy. Int J Clin Oncol 5: 200-203

Kerekes P, Sharma PN, Brossi A, Chignell CF, Quinn FR (1985) Synthesis and biological effects of novel thiocolchicines. 3. Evaluation of N-acyldeacetylthiocolchicines, N-(alkoxycarbonyl) deacetylthiocolchicine and O-ethyldemethylthiocolchicines. New synthesis of thiodemecolcine and antileukemic effects. J Med Chem 28: 1204-1208

Kerr DJ, Rustin GJ, Kaye SB, Bleehen N, Harper P, Brampton MH (1995) Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer. Br J Cancer 72: 1257-1269

Kinghorn AD, Balandrin MF (1993) Human medicinal agents from plants. ACS Symposium Series 534. American Chemical Society, Washington

Kita T, Kikuchi Y, Kudoh K, Takano M, Goto T, Llirata J, Tode T, Nagata I (2000) Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary. Oncol Rep 7: 327-331

Koshiyama M, Fujii H, Kinezaki M, Ohgi S, Konishi M, Hidetaka N, Hayashi M, Yoshida M (2000) Chemosensitivity testing of irinotecan (CPT-11) in ovarian and endometrial carcinomas: A comparation with cisplatin. Anticancer Res 20(3A): 1353-1358

Kovacs E, Hajto T, Hostanska K (1991) Improvement of DNA repair in lymphocytes of breast cancer patients treated with Viscum album extract (Iscador). Eur J Cancer 27:1672-1676

Koyama H, Katabuchi H, Tanaka N, Matsuura K, Okura H (1998) Prognosis and ovary function in patients with malignant ovarian tumors after fertility conserving surgery and chemotherapy. Jap J Fert Ster 43: 209-214

Lambert HE, Soutter WP (1990) Ovary, vagina and vulva. In: Treatment of cancer (Eds Sikora K, Halman KE). Chapman and Hall Medical, London, 549-561

Le-Donne M, Messina G, Buda C, Corrado F, Pettineo G, Salimbeni V, Irato S (1997) Intraperitoneal chemotherapy with mitoxantrone in ovary cancer. Tumori 83: 837-840

Lee EB, Yun HS, Woo WS (1977) Plants and animals used for fertility regulation in Korea. Korean J Pharmacog 8: 81-87

Leroi R (1977) Postoperative Viscum album therapy after surgery of breast neoplasms. Helv Chir Acta 44: 403-414

Lev LM, Posada Jr JG (1983) Aclarubicin: status of phase 1 and 2 studies in the United States. Cancer Treat Symp 1: 65-69

Levi J, Sharoni Y (1994) Pharmaceutical preparations containing lycopene as neoplasm inhibitor. Patent-Eur Appl-600, 544, 27pp

Li X, Liu L, Wu L (2000) Ifosfamide combination chemotherapy for advanced gynecologic malignancies. Zhonghua Zhongliu Zazhi 22: 330-332

Malfetano JH, Blessing JA, Jacobs AJ (1993) A phase II trial of didemnin B in patients with previously treated epithelial ovarian cancer. A gynecologic oncology group study. Am J Clin Oncol 6: 47-49

Markman M, Kennedy A, Webster K, Peterson G, KuIp B, Belinson J (2000) Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol 19: 1901-1905

Mattern J, Wayss K, Volm M (1984) Effect of five antineoplastic agents on tumor xenografts with different growth rates. J Nat Cancer Inst 72: 1335-1339

McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ (2000) Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A ginecologic oncology group study. I Clin Oncol 18: 1062-1067

Moura MD, Torres AR, Oliveira RAG, Diniz MFFM, Barbosa-Filho JM (2001) Natural products inhibitors of models of mammary neoplasia. British Journal of Phytotherapy 5(3): 124-145

Moura MD, Silva IS, Oliveira RAG, Diniz MFFM, Barbosa-Filho JM (2002) Natural products inhibitors of uterine cervical neoplasia. Acta Farm Bonaerense 21(1): 67-74

Muanza DN, Euler KL, Williams L, Newman DI (1995) Screening for antitumor and anti-HIV activities of nine medicinal plants from Zaire. Int J Pharmacog 33: 98-106

Muss HB, Blessing IA, Baker VV, Barnhill DR, Adelson MD (1990) Echinomycin in advanced ovarian cancer. A phase II trial of the gynecologic oncology group. Am J Clin Oncol 13: 299-301

Nakata HY, Kikuch YH, Tode TH, Hirata I, Kita TK, Ishii KJ, Kudoh KY, Nagata IH, Shinomiya NY (1998) Inhibitory effects of ginsenoside rh2 on tumor growth in nude mice bearing human ovarian cancer cells. Jap J Cancer Res 89: 733-740

Papadimitriou CA, Moulopoulos LA, Vlahos G, Voulgaris Z, Kiosses E, Dimooulos MA (2000) Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: Long term results of a phase II study. Cancer 89: 1547-1554

Parker RJ, Adamson RH, Douros JD, Sieber SM (1983) Comparative pharmacologic studies of dactinomycin and pip-1-beta actinomycin. Cancer Treat Symp 1: 45-50

Patsner B (1998) Ovarian epithelial carcinoma metastasis to the chroid of the eye: Prolonged survival with radiation and taxol chemotherapy. Eur J Gynecol Oncol 19: 345-346

Peeorelli S, Wagenaar HC, Vergote IB, Curran D, Beex IVA, Wiltshaw F, Vermorken JB (1999) Cisplatin, vinblastine and bleomycin combination chemotherapy in recurrent or advanced granulosa (-theca) cell tumours of the ovary. An EORTC Gynaecological Cancer Cooperative Group Study. Eur J Cancer 35: 1331-1337

Pettit GR, Gaddamidi V, Herald DL, Singh SB, Cragg GM, Schmidt IM, Boettner FE, Williams M, Sagawa Y (1986) Antineoplastic agents. 120. Pancratium littorale. I Nat Prod 49: 995-1002

Pettit GR, Kamano Y, Herald CL, Fujii Y, Kizu H, Boyd MR. Boettner FE, Doubek DL, Schmidt IM, Chapuis IC, Michel C (1993) Isolation of dolastatins 10-15 from the marine mollusc Dolabella auricularia. Tetrahedron 49: 9151-9170

Pettit GR, Pierson FH, Herald CL (1994) Anticancer drugs from animals, plants and microorganisms. John Wiley & Sons, ING, New York

Pfisterer J (2000) Refinement of primary chemotherapy for advanced ovarian cancer. Onkologie 23(Suppl 2): 31-34

Pihl A, Fodstad O (1983) Cancerostatic lectins. Developments in Oncology 15: 134-141

Pihl A, Fodstad O, Olsnes S (1980) Anticancer properties of the toxic lectins abrin and ricin. Protides Biological Fluids 27: 631-636

Platt JS, Rogers S, Flynn EA, Taylor RR (1999) Primary angiosarcoma of the ovary: A case report and review of the literature. Gynecol Oncol 73: 443-446

Pratesi G, Manzotti C, Tortoreto M, Audisio RA, Zunino F (1991) Differential efficacy of flavone acetic acid against liver versus lung metastases in a human tumour xenograft. Br J Cancer 63: 71-74

Pujade LE, Guastalla JP, Vicent P (2000) Carbolatin in ovarian cancers. Bull Cancer Montrouge 87: 40-47

Radisky DC, Radisky ES, Barrows LR, Copp BR, Kramer RA, Ireland CM (1993) Novel cytotoxic topoisomerase II inhibiting pyrroloiminoquinones from fijian sponges of the genus Zyzzya. J Am Chem Soc 115: 1632-1638

Rinehart KL (2000) Antitumor compounds from Tunicates. Med Res Rev 20: 1-26

Rinehart KL, Sakai R (1995) Ecteinascidins from Ecteinascidia turbinata as neoplasm inhibitors. Patent-US-5,478,932, 6 pp

Saha JC, Savini EC, Kasinathan S (1961) Ecbolic properties of Indian medicinal plants. Part 1. Indian J Med Res 49: 130-151

Schink JC, Weller E, Harris LS, Cella D, Gerstner J, Falkson C, Wadler S (2001) Outpatient taxol and carboplatin chemotherapy for suboptmially debulked epithelial carcinoma of the ovary results in improved quality of life: An Eastern Cooperative Oncology Group phase II study (E2E93). Cancer J7: 155-164

Schultze JL, Stettin A, Berg A (1991) Demonstration of a specifically aqueous mistletoe extract (Viscum album L). Klin Wochensch 69: 397-403

Schultze RM, Merriman RL, Andis SL, Bonjouklian R, Grindey GB, Rutherford PG, Gallegos A, Massey K, Powis G (1995) In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res 15: 1135-1139

Shimizu Y, Umezawa S, Hasumi K (1998) A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma. Ann Acad Med Singapore 27: 650-656

Sreejith G, Gangadharan VP, Elizabath KA, Preetha S, Chithrathara K (2000) Primary granulocytic sarcoma of the ovary. Am J Clin Oncol 23: 239-240

Sumi T, Ishiko O, Yoshida H, Ogita S (2000) Bleomycin, actinomycin-D, and cisplatin treatment of ovarian germ-cell malignancies contributes to reducing adverse drug reactions. Oncol Rep 7: 1235-1238

Sun LC (1964) On the brew "Sheng-Hua Tang". Fu-Chien Chung-I-Yao 1: 41-42

Takizawa K, Satow YI, Kato Y, Kawana T (1997) Two patients with ovarian cancer refractory to cisplatin-based chemotherapy managed by new combination chemotherapy with irinotecan hydrochloride and mitomycin-C. Intl Clin Oncol 2: 238-242

Tanaka NG, Sakamoto N, Inoue K, Korenaga H, Kadoya S, Ogawa H, Osada Y (1989) Antitumor effects of an antiangiogenic polysaccharide from an Arrhrobacter species with or without a steroid. Cancer Res. 49: 6727-6730

Tode T, Kikuchi Y, Kita T, Hirata J, Imaizumi E, Nagata I (1993) Inhibitory effects by oral administration of ginsenoside rh2 on the growth of human ovarian cancer cells in nude mice. J. Cancer Res. Clin Oncol 120: 24-26

Topuz E, Saip P, Aydiner A, Salihoglu Y, Berkan S, Bengisu E (1998) Intraperitoneal cisplatin-mitoxantrone and intravenous ifosfamide combination as first-line treatment of ovarian cancer. Eur J Gynecol Oncol 19: 265-270

Tung TC, Lin JY, Hsu CT (1975) Some aspects on mechanism of anti-cancer activity of abrin. Toxicon 13: 127-128

Twu NF, Juang C, Yeng S, Lu CI, Lai CZ, Chao KC (1999) Treatment of primary pure angiosarcoma of ovary with multiple lung metastases: A case report. Eur J Gynecol Oncol 20: 383-385

Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, Shimomura K (1994) FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antituor activities on experimental tumors in mice. J Antibiot 47: 315-423

Umezawa S, Shiizu Y, Takeshima N, Hasui K (1996) Chemotherapy for ovarian clear cell adenocarcinoma with irinotecan hydrochloride and mitoycin C. Intl J Clin Oncol 1: 157-162

Vasey PA, Paul J, Bir. A, Junor EJ, Reed NS, Symonds RP, Atkinson R, Kaye SB (1999) Docetaxel and cisplatin in combination as first- line chemotherapy for advanced epithehal ovarian cancer. J Clin Oncol 17: 2069-2080

Yokoyama Y, Futagam M, Fukushi Y, Sakamoto T, Higuchi T, Fujii S, Sato S, Takami H, Saito Y (2000) Secondary acute nonlyphocytic leukemia following successful chemotherapy combining cisplatin, doxorubicin, and cyclophosphamide for stage IV epithelial ovarian cancer. Arch Gynecol Obstet 263: 206-207

Young JA, Westlake D, Schnetzer GW, Keller AM, Sexauer JM, Newcomer LN (1985) Phase I study of divided-dose vinblastine in advanced malignancy. Cancer Treat Rep 69: 607-610

Zee-Cheng RKY (1997) Anticancer research on Loranthaceae plants. Drugs of the Future 22: 519-530


J. M. Barbosa-Filho, Laboratorio de Tecnologia Farmaceutica, Universidade Federal da Paraiba, Caixa Postal 5009, 5805 1-970, Joao Pessoa, PB, Brazil

Tel/Fax: ++55-83-216-7364;

COPYRIGHT 2003 Urban & Fischer Verlag
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Silva, J.S.; Moura, M.D.; Oliveira, R.A.G.; Diniz, M.F.F.; Barbosa-Filho, J.M.
Publication:Phytomedicine: International Journal of Phytotherapy & Phytopharmacology
Geographic Code:1USA
Date:Mar 1, 2003
Previous Article:Efficacy of dry extract of ivy leaves in children with bronchial asthma--a review of randomized controlled trials. (Review).
Next Article:A review on potentiality of medicinal plants as the source of new contraceptive principles. (Review).

Related Articles
Introgen obtains patent for p53 targeted chemotherapy.
Epidemiology of ovarian cancer and improving survival.
Alpha-lipoic acid modulates ovarian surface epithelial cell growth.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters